查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1672920

PARP 抑制劑市場：按藥物類型、應用、分銷管道和地區分類

PARP Inhibitor Market, By Drug Type, By Application, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 147 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025 年全球 PARP 抑制劑市場規模估計為 78.5 億美元，預計到 2032 年將達到 143.6 億美元，2025 年至 2032 年的複合年成長率為 9.0%。

報告範圍 報告詳細資訊
基準年 2024 2025 年市場規模 78.5億美元
效能資料 2020-2024 預測期 2025-2032
預測期：2025 年至 2032 年複合年成長率 9.00％ 2032 年金額預測 143.6億美元
數字。 2025 年 PARP 抑制劑市場佔有率（按地區）
PARP 抑制劑市場-IMG1

聚（ADP-核糖）聚合酵素(PARP) 抑制劑是一種主要用於治療癌症的標靶治療。它們透過阻斷修復受損 DNA 的 PARP 酶發揮作用，從而幫助化療和放射線治療更有效地殺死癌細胞。全球 PARP 抑制劑市場的成長得益於癌症發生率的上升以及 PARP 抑制劑在癌症治療中的核准和採用的增加。該市場的領先藥物包括奧拉帕尼、尼拉帕尼和魯卡帕尼，這些藥物在治療乳腺癌、卵巢癌和前列腺癌方面已被證實有效。隨著對 PARP 抑制劑在新型癌症和聯合治療中的潛力進行研究評估，該市場可能會繼續成長。

市場動態

全球 PARP 抑制劑市場的成長得益於全球癌症發病率的不斷上升以及 PARP 抑制劑在腫瘤學領域的核准和採用日益增多。根據世界衛生組織統計，2018年癌症病例數和死亡人數分別增加至1,810萬人和960萬人。持續進行臨床試驗以評估PARP抑制劑在更廣泛患者群體中的療效以及與其他抗癌治療的聯合使用，可能會推動市場成長。然而，PARP 抑制劑價格高昂、需要進行基因預篩檢以選擇患者以及實施嚴格的藥物核准監管途徑可能會阻礙市場成長。對新應用和新藥研發的持續研究可能在不久的將來為市場成長提供新的機會。

研究的主要特點

  • 本報告對全球 PARP 抑制劑市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設 2024 年為基準年。
  • 它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。
  • 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
  • 全球 PARP 抑制劑市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數進行的分析。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
  • 全球 PARP 抑制劑市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
  • 相關人員可以透過全球 PARP 抑制劑市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要
  • 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 影響分析
  • 市場趨勢
  • 監管情景
  • 收購和合作場景
  • 資金籌措和投資
  • PEST分析
  • 波特的分析

4.全球PARP 抑制劑市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • 整體影響
  • 政府舉措
  • COVID-19 市場影響

5. 2020-2032 年全球 PARP 抑制劑市場（按藥物類型分類）（十億美元）

  • 介紹
  • 尼拉帕尼
  • 奧拉帕尼
  • 魯卡帕尼
  • 他拉唑帕尼
  • Veliparib
  • 其他

6.全球PARP 抑制劑市場，按應用分類，2020-2032 年（十億美元）

  • 介紹
  • 卵巢癌
  • 輸卵管癌
  • 乳癌
  • 攝護腺癌
  • 胰臟癌
  • 其他

7. 2020-2032 年全球 PARP 抑制劑市場按分銷管道分類（十億美元）

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

8.全球PARP 抑制劑市場，按地區，2020-2032 年（十億美元）

  • 介紹
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭格局

  • 公司簡介
    • AstraZeneca
    • GlaxoSmithKline
    • Merck Co. &Inc
    • AbbVie Inc
    • Clovis Oncology
    • Medivation
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • KaryopharmTherapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

第 10 章分析師建議

  • 興衰
  • 一致的機會地圖

第 11 章 參考文獻與調查方法

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI3037

Global PARP Inhibitor Market is estimated to be valued at USD 7.85 Bn in 2025 and is expected to reach USD 14.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 7.85 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 9.00% 2032 Value Projection: USD 14.36 Bn
Figure. PARP Inhibitor Market Share (%), By Region 2025
PARP Inhibitor Market - IMG1

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted therapies used mainly in cancer treatment. These work by blocking the action of PARP enzymes that repair damaged DNA, thus, helping chemotherapy and radiotherapy kill cancer cells more effectively. Global PARP inhibitor market growth is driven by rising cancer incidence, increasing approval and adoption of PARP inhibitors in oncology. Key drugs in the market include Olaparib, Niraparib and Rucaparib which have demonstrated efficacy in treating cancers like breast, ovarian and prostate. With ongoing research evaluating the potential of PARP inhibitors in newer cancer types and combination therapies, the can witness growth.

Market Dynamics:

Global PARP inhibitor market growth is primarily driven by increasing prevalence of cancer worldwide coupled with growing approval and adoption of PARP inhibitors in oncology. According to WHO, cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Continuous clinical trials evaluating the efficacy of PARP inhibitors in broader patient segments and combination with other anti-cancer therapies can drive the market growth. However, high cost of PARP inhibitors, requirement of genetic pre-screening for patient selection and imposition of stringent regulatory pathways for drug approval can hamper the market growth. Ongoing research exploring newer applications and emerging pipeline drugs can offer new opportunities for market growth in the near future.

Key Features of the Study:

  • This report provides in-depth analysis of the global PARP inhibitor market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global PARP inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AstraZeneca, Clovis Oncology, TESARO, AbbVie, Pfizer, Merck KGaA
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation-

  • By Drug Type
    • Niraparib
    • Olaparib
    • Rucaparib
    • Talazoparib
    • Veliparib
    • Others
  • By Application
    • Ovarian Cancer
    • Fallopian Tube Cancer
    • Breast Cancer
    • Prostate Cancer
    • Pancreatic Cancer
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca
    • GlaxoSmithKline
    • Merck Co. & Inc
    • AbbVie Inc
    • Clovis Oncology
    • Medivation
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • Repare Therapeutics, Inc.
    • Genentech, Inc.
    • Artios Pharma
    • Sierra Oncology, Inc.
    • KaryopharmTherapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Application
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global PARP Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global PARP Inhibitor Market, By Drug Type, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Niraparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Olaparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rucaparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Talazoparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Veliparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global PARP Inhibitor Market, By Application, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Ovarian Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Fallopian Tube Cancer
    • Mammography
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Breast Cancer
    • Chest X-ray
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Prostate Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pancreatic Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global PARP Inhibitor Market, By Distribution Channel, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global PARP Inhibitor Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • AstraZeneca
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GlaxoSmithKline
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck Co. & Inc
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AbbVie Inc
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Clovis Oncology
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Medivation
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • KaryopharmTherapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About Us and Sales Contact